Cargando…

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity

Germline TSC1 or TSC2 mutations cause Tuberous Sclerosis Complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice were generated in which Tsc1 loss and Kras(G12D) expression occur in a small fraction of lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Mei-Chih, Ma, Jian, Chen, Liang, Kozlowski, Piotr, Qin, Wei, Li, Danan, Shimamura, Takeshi, Thomas, Roman K., Hayes, D. Neil, Meyerson, Matthew, Kwiatkowski, David J., Wong, Kwok-Kin
Formato:	Texto
Lenguaje:	English
Publicado:	2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841700/ https://www.ncbi.nlm.nih.gov/pubmed/19966866 http://dx.doi.org/10.1038/onc.2009.452

Ejemplares similares

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1(+/−) Mice
por: Shen, Ming Hong, et al.
Publicado: (2017)

Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example
por: Marcinkowska, Malgorzata, et al.
Publicado: (2010)

A brain proteomic investigation of rapamycin effects in the Tsc1(+/−) mouse model
por: Wesseling, Hendrik, et al.
Publicado: (2017)

Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2
por: Kwiatkowski, David J, et al.
Publicado: (2015)

Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing
por: Tyburczy, Magdalena E., et al.
Publicado: (2015)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in Tsc-1-Suppressed Brain
por: Cox, Rebecca L., et al.
Publicado: (2018)

Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development
por: Giannikou, Krinio, et al.
Publicado: (2016)

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer
por: Huang, Qingyuan, et al.
Publicado: (2022)

The TSC1-TSC2 complex consists of multiple TSC1 and TSC2 subunits
por: Hoogeveen-Westerveld, Marianne, et al.
Publicado: (2012)

Induction by rapamycin and proliferation‑promoting activity of Hspb1 in a Tsc2‑deficient cell line
por: Kitano, Takayuki, et al.
Publicado: (2023)

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
por: Mrozek, Evelyn M., et al.
Publicado: (2021)

Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC)
por: Auricchio, Neil, et al.
Publicado: (2012)

Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells
por: Himes, Blanca E., et al.
Publicado: (2018)

CD4(+)CD25(−)Nrp1(+) T Cells Synergize with Rapamycin to Prevent Murine Cardiac Allorejection in Immunocompetent Recipients
por: Yuan, Qing, et al.
Publicado: (2013)

Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin
por: Sundberg, Maria, et al.
Publicado: (2018)

Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy
por: Papadakis, Michalis, et al.
Publicado: (2013)

Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex
por: Mozaffari, Melika, et al.
Publicado: (2009)

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
por: Haines, Eric, et al.
Publicado: (2018)

Identification of FIP200 interaction with the TSC1–TSC2 complex and its role in regulation of cell size control
por: Gan, Boyi, et al.
Publicado: (2005)

Stochastic Model of Tsc1 Lesions in Mouse Brain
por: Prabhakar, Shilpa, et al.
Publicado: (2013)

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2017)

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer
por: Scott, Kenneth L., et al.
Publicado: (2009)

Evidence for population variation in TSC1 and TSC2 gene expression
por: Jentarra, Garilyn M, et al.
Publicado: (2011)

AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2
por: Lin, Hui-Ping, et al.
Publicado: (2015)

Angiomyolipoma Have Common Mutations in TSC2 but No Other Common Genetic Events
por: Qin, Wei, et al.
Publicado: (2011)

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
por: Shi, Pei-Jie, et al.
Publicado: (2016)

Rapamycin Synergizes with Cisplatin in Antiendometrial Cancer Activation by Improving IL-27–Stimulated Cytotoxicity of NK Cells
por: Zhou, Wen-Jie, et al.
Publicado: (2017)

Correction: Stochastic Model of Tsc1 Lesions in Mouse Brain
por: Prabhakar, Shilpa, et al.
Publicado: (2013)

Analysis of the TSC1and TSC2genes in sporadic renal cell carcinomas
por: Parry, L, et al.
Publicado: (2001)

Mutation spectrums of TSC1 and TSC2 in Chinese women with lymphangioleiomyomatosis (LAM)
por: Liu, Jie, et al.
Publicado: (2019)

Germline mutation of TSC1 or TSC2 gene in Chinese patients with bilateral renal angiomyolipomas and mutation spectrum of Chinese TSC patients
por: Jiangyi, Wang, et al.
Publicado: (2020)

Nipple angiofibromas with loss of TSC2 are associated with tuberous sclerosis complex
por: Nathan, Neera, et al.
Publicado: (2015)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
por: Chan, Lok Seng, et al.
Publicado: (2023)

Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex
por: Li, Yi, et al.
Publicado: (2018)

Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
por: Rosengren, Thomas, et al.
Publicado: (2020)

Correction: Mutation spectrums of TSC1 and TSC2 in Chinese women with lymphangioleiomyomatosis (LAM)
por: Liu, Jie, et al.
Publicado: (2020)

Notch transactivates Rheb to maintain the multipotency of TSC-null cells
por: Cho, Jun-Hung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bags1fa3f62nado6lp2h80j8ic